Elicio Therapeutics Inc
NASDAQ:ELTX
Elicio Therapeutics Inc
Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. The company is headquartered in Boston, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. The company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The firm is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The firm provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The firm conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. The company is headquartered in Boston, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. The company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The firm is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The firm provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The firm conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
